← Eichor
Condition: Serous Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Serous Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · 27 location(s) · National Cancer Institute (NCI) · NCT04633239MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3 · 53 location(s) · Swiss GO Trial Group · NCT04111978Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
Phase 2 · 2 location(s) · Prakash Pandalai · NCT04779554Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
NA · 1 location(s) · Institut du Cancer de Montpellier - Val d'Aurelle · NCT04024917This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Phase 2 · 3 location(s) · Yale University · NCT02491099Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Phase 2 · 2 location(s) · Joyce Liu, MD · NCT06369155Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients
Phase 2 · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06800391Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)
Phase 3 · 1 location(s) · University of Southampton · NCT06513065Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
Phase 2 · 12 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT05872204Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
Phase 2 · 1 location(s) · University of California, Irvine · NCT07693452ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT05542407Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
Phase 3 · 19 location(s) · Ente Ospedaliero Ospedali Galliera · NCT05601700BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
Phase 2 · 1 location(s) · Barbara Malene Fischer · NCT07629609Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480954Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Phase 2 · 1 location(s) · Shandong University · NCT04716686Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC
NA · 1 location(s) · Turku University Hospital · NCT04846933Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · 409 location(s) · National Cancer Institute (NCI) · NCT05256225Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Phase 2 · 3 location(s) · Centre Oscar Lambret · NCT05500391A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/Phase 2 · 14 location(s) · Volastra Therapeutics, Inc. · NCT05902988Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Phase N/A · 1 location(s) · Oslo University Hospital · NCT02073500A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Phase 1 · 17 location(s) · NextCure, Inc. · NCT06792552InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT05463796First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Phase 1/Phase 2 · 16 location(s) · Scancell Ltd · NCT05329532Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management.
Phase N/A · 1 location(s) · Jules Bordet Institute · NCT07451483Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT00488878Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re
Phase 2 · 2 location(s) · Roswell Park Cancer Institute · NCT05231122
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.